
|Articles|September 18, 2015
Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
There are many clinical trial opportunities, Tolaney says, before surgery.
Advertisement
Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.
“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
KTX-1001 Elicits Responses in Some With Multiple Myeloma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
5




